Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data

Background Randomised controlled trials of adjunctive vitamin D in pulmonary tuberculosis (TB) treatment have yielded conflicting results. Individual participant data meta-analysis could identify factors explaining this variation. Methods We meta-analysed individual participant data from randomised controlled trials of vitamin D in patients receiving antimicrobial therapy for pulmonary TB. Primary outcome was time to sputum culture conversion. Secondary outcomes were time to sputum smear conversion, mean 8-week weight and incidence of adverse events. Pre-specified subgroup analyses were done according to baseline vitamin D status, age, sex, drug susceptibility, HIV status, extent of disease and vitamin D receptor genotype. Results Individual participant data were obtained for 1850 participants in eight studies. Vitamin D did not influence time to sputum culture conversion overall (adjusted HR 1.06, 95% CI 0.91–1.23), but it did accelerate sputum culture conversion in participants with multidrug-resistant pulmonary TB (adjusted HR 13.44, 95% CI 2.96–60.90); no such effect was seen in those whose isolate was sensitive to rifampicin and/or isoniazid (adjusted HR 1.02, 95% CI 0.88–1.19; p-value for interaction=0.02). Vitamin D accelerated sputum smear conversion overall (adjusted HR 1.15, 95% CI 1.01–1.31), but did not influence other secondary outcomes. Conclusions Vitamin D did not influence time to sputum culture conversion overall, but it accelerated sputum culture conversion in patients with multidrug-resistant pulmonary TB. A meta-analysis of individual participant data from clinical trials reports that adjunctive vitamin D accelerates sputum culture conversion in patients with multidrug-resistant tuberculosis, but not in those with drug-sensitive disease http://ow.ly/f2oN30n2OxJ

[1]  David A. Jolliffe,et al.  Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials , 2019, Thorax.

[2]  C. Sempos,et al.  Prevalence and determinants of QuantiFERON-diagnosed tuberculosis infection in 9,810 Mongolian schoolchildren. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Hong-xia Wu,et al.  Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis , 2018, BMC Pulmonary Medicine.

[4]  Mitsuyoshi Urashima,et al.  Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. , 2017, The Lancet. Respiratory medicine.

[5]  David A. Jolliffe,et al.  High‐Dose Vitamin D3 during Tuberculosis Treatment in Mongolia. A Randomized Controlled Trial , 2017, American journal of respiratory and critical care medicine.

[6]  A. Farazi,et al.  The effect of vitamin D on clinical outcomes in tuberculosis , 2017 .

[7]  David A. Jolliffe,et al.  Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data , 2017, British Medical Journal.

[8]  Alimuddin Zumla,et al.  Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review , 2016, Open forum infectious diseases.

[9]  C. del Rio,et al.  High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial. , 2015, The American journal of clinical nutrition.

[10]  R. Raqib,et al.  Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial , 2015, PloS one.

[11]  D. Christopher,et al.  Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Infectious diseases.

[12]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[13]  R. Hafner,et al.  Advancing host-directed therapy for tuberculosis , 2015, Nature Reviews Immunology.

[14]  David A. Jolliffe,et al.  Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. , 2015, The Lancet. Respiratory medicine.

[15]  Liyun Shi,et al.  Impact of vitamin D supplementation on the outcome of tuberculosis treatment: a systematic review and meta‐analysis of randomized controlled trials , 2014, Chinese medical journal.

[16]  A. Ralph,et al.  L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial , 2013, PloS one.

[17]  K. Fielding,et al.  An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse , 2013, PloS one.

[18]  Z. Hasan,et al.  Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’ , 2013, BMC Infectious Diseases.

[19]  V. Sreenivas,et al.  Risk and outcome of multidrug-resistant tuberculosis: vitamin D receptor polymorphisms and serum 25(OH)D. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  Robert J Wilkinson,et al.  Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa , 2011, Proceedings of the National Academy of Sciences.

[21]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[22]  R. Wilkinson,et al.  High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial , 2011, The Lancet.

[23]  T. Sudarsanam,et al.  Nutritional supplements for people being treated for active tuberculosis. , 2011, The Cochrane database of systematic reviews.

[24]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[25]  M. Sodemann,et al.  Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. , 2009, American journal of respiratory and critical care medicine.

[26]  Robert J Wilkinson,et al.  IFN-γ- and TNF-Independent Vitamin D-Inducible Human Suppression of Mycobacteria: The Role of Cathelicidin LL-371 , 2007, The Journal of Immunology.

[27]  R. Wilkinson,et al.  Vitamin D in the treatment of pulmonary tuberculosis , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[29]  C. Rumende,et al.  The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. , 2006, Acta medica Indonesiana.

[30]  F. Anderson.  Nutrition and bone health: with particular reference to calcium and vitamin D. Report of the Subgroup on Bone Health, Working Group on the Nutritional Status of the Population of the Committee on Medical Aspects of the Food Nutrition Policy. , 1999, Reports on health and social subjects.